文献速递肺栓塞与肺血管病呼吸道感染

新冠后慢性血栓栓塞性肺动脉高压并不常见:英国国家监测与观察性筛查队列研究

Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies.
PubMed 文献 · Eur Respir J · 2024-08-29

该研究评估英国2017—2022年全国多学科团队(MDT)的CTEPD/CTEPH转诊量,并在1094例新冠住院患者出院后中位5个月用症状、心电图和NT-proBNP风险评分筛查。大流行第二年CTEPH诊断量已回到疫情前基线,仅少数CTEPH可能归因于新冠相关肺栓塞,提示新冠住院后CTEPH的预估风险较低。

要点

  • 大流行第二年CTEPH月诊断量已回到疫情前基线水平
  • 确诊CTEPD/CTEPH中仅少数可能与新冠相关肺栓塞有关
  • 新冠住院后中位5个月用简单临床评分筛查出的高危者中无人确诊CTEPH

核心结论

  • 新冠住院后发生CTEPH的预估风险较低。
  • 简单风险评分是筛查患者以进一步检查的潜在有效方式。

研究设计与样本

  • 通过英国国家MDT评估2017—2022年CTEPD/CTEPH转诊率,以历史年份为对照。
  • 另有多中心队列纳入1094例新冠住院患者(平均年龄58岁,60.4%男性),出院后中位5个月用症状、心电图和NT-proBNP风险评分计算CTEPH风险。

主要发现

  • 大流行第二年CTEPH诊断量回到疫情前基线(每月23.1例对27.8例;p=0.252)。
  • 334例确诊CTEPD/CTEPH中,4例(1.2%)CTEPH可能与新冠相关肺栓塞有关,另3例(0.9%)为不伴肺动脉高压的CTEPD。
  • 1094例筛查患者中11例(1.0%)随访时CTEPH高风险,但均未获国家MDT确诊CTEPH。

关键数值与推荐

  • CTEPH月诊断量比较:23.1对27.8例/月,p=0.252。
  • CTEPH可能与新冠相关肺栓塞有关者占1.2%(4/334);不伴肺动脉高压的CTEPD占0.9%(3/334)。
  • 新冠住院筛查队列1094例中CTEPH高风险者占1.0%(11例)。
  • 筛查时点为出院后中位5个月,依据症状、心电图和NT-proBNP的现有风险评分。

临床怎么用

  • 对新冠住院后患者可按症状、心电图和NT-proBNP风险评分进行筛查分流。
  • 评分高危者应转诊进一步评估,但研究中高危者均未确诊CTEPH,需注意避免过度诊断。

局限性

  • 筛查队列为观察性设计,CTEPH确诊依赖国家MDT评估。
  • 随访时点为出院后中位5个月,长期风险未在此摘要中说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary embolism (PE) is a well-recognised complication of coronavirus disease 2019 (COVID-19) infection, and chronic thromboembolic pulmonary disease with and without pulmonary hypertension (CTEPD/CTEPH) are potential life-limiting consequences. At present the burden of CTEPD/CTEPH is unclear and optimal and cost-effective screening strategies yet to be established. METHODS: We evaluated the CTEPD/CTEPH referral rate to the UK national multidisciplinary team (MDT) during the 2017-2022 period to establish the national incidence of CTEPD/CTEPH potentially attributable to COVID-19-associated PE with historical comparator years. All individual cases of suspected CTEPH were reviewed by the MDT for evidence of associated COVID-19. In a separate multicentre cohort, the risk of developing CTEPH following hospitalisation with COVID-19 was calculated using simple clinical parameters at a median of 5 months post-hospital discharge according to existing risk scores using symptoms, ECG and N-terminal pro-brain natriuretic peptide. RESULTS: By the second year of the pandemic, CTEPH diagnoses had returned to the pre-pandemic baseline (23.1 versus 27.8 cases per month; p=0.252). Of 334 confirmed CTEPD/CTEPH cases, four (1.2%) patients were identified to have CTEPH potentially associated with COVID-19 PE, and a further three (0.9%) CTEPD without PH. Of 1094 patients (mean age 58 years, 60.4% male) hospitalised with COVID-19 screened across the UK, 11 (1.0%) were at high risk of CTEPH at follow-up, none of whom had a diagnosis of CTEPH made at the national MDT. CONCLUSION: A priori risk of developing CTEPH following COVID-19-related hospitalisation is low. Simple risk scoring is a potentially effective way of screening patients for further investigation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Reddy SA, Newman J, Leavy OC, et al. Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies. Eur Respir J. 2024. PMID: 39060016. doi:10.1183/13993003.01742-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。